MRNA
Moderna, Inc.
48.91
1 x 45.77
1 x 50.94
bid
ask
-
1.12
2.24%
03:45 PM
timesize
Ytd 65.85%
1y 106.81%
47.93
day range
49.88
22.36
52 week range
57.80
Open 48.31 Prev Close 50.03 Low 47.93 High 49.88 Mkt Cap 19.37B
Vol 5.35M Avg Vol 8.08M EPS -8.14 P/E N/A Forward P/E -12.12
Beta 1.06 Short Ratio 10.34 Inst. Own 76.57% Dividend N/A Div Yield N/A
Ex Div Date N/A Earning 07-31 50-d Avg 51.45 200-d Avg 36.48 1yr Est 43.37
Earning
Date For Estimate Reported Surprise surprise %
2026-05-01 2026-03 0 N/A 1.84 60.93%
2026-02-13 2025-12 0 N/A 0.49 18.85%
2026-02-13 2025-12 0 N/A N/A N/A
2025-11-06 2025-09 0 N/A N/A N/A
2025-11-06 2025-09 0 N/A 1.64 76.28%
2025-08-01 2025-06 0 N/A 0.86 28.76%
Upgrade / Downgrade
Date Firm Action From To
2026-05-04 UBS Upgrade Neutral Neutral
2026-05-04 Goldman Sachs Upgrade Neutral Neutral
2026-05-04 Evercore ISI Group Upgrade In-Line In-Line
2026-05-04 RBC Capital Upgrade Sector Perform Sector Perform
2026-04-02 Barclays Upgrade Equal-Weight Equal-Weight
2026-02-23 Piper Sandler Upgrade Overweight Overweight
Profile
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Insider Holder
Date Name Relation Quantity Description
2025-12-10 AFEYAN NOUBAR BOGHOS Director 0.00 Conversion of Exercise of derivative security
2026-02-10 BANCEL STEPHANE J Chief Executive Officer 21.96M Stock Award(Grant)
2026-02-26 HOGE STEPHEN President 1.63M Conversion of Exercise of derivative security
2026-04-29 HORNING SANDRA Director 18.59K Conversion of Exercise of derivative security
2026-04-30 HUSSAIN SHAH ABBAS Director 12.07K Sale
2026-03-04 KLINGER SHANNON THYME Officer 65.78K Conversion of Exercise of derivative security
Institution Ownership
Report Date Organization Position Value Percentage
2026-03-30 Blackrock Inc. 29.64M 1.48B 7.47%
2025-12-30 FMR, LLC 28.05M 1.40B 7.07%
2026-03-30 Vanguard Capital Management LLC 22.87M 1.14B 5.76%
2026-03-30 BAILLIE GIFFORD & CO 19.99M 999.89M 5.04%
2026-03-30 Capital World Investors 18.70M 935.45M 4.71%
2025-12-30 State Street Corporation 16.37M 818.76M 4.12%
Fund Ownership
Report Date Organization Position Value Percentage
2026-03-30 GROWTH FUND OF AMERICA 12.50M 625.37M 3.15%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund 11.02M 551.46M 2.78%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard 500 Index Fund 8.77M 438.71M 2.21%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund 7.98M 399.20M 2.01%
2026-02-27 VANGUARD WORLD FUND-Vanguard International Growth Fund 5.97M 298.55M 1.50%
2026-03-30 Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund 5.26M 263.04M 1.33%
Split
Split Date
1 : 10 2017-08-03